Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Philip Morris International Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.66 (market cap $39.89B), while Philip Morris International Inc. trades at $182.52 (market cap $283.07B). The key difference: Philip Morris International Inc. is far larger — about 7.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Philip Morris International Inc. pays a 3.24% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PM | |
|---|---|---|
Market Cap | $39.89B | $283.07B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $191.86 |
52-Week Low | $278.09 | $144.33 |
Enterprise Value | $38.15B | $329.56B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Philip Morris International (PM) trades at $181.62, up 0.25% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company maintains robust profitability with a 26.74% net income margin. However, a recent $500 million impairment charge and lowered profit guidance due to cost pressures and currency swings present near-term headwinds. The stock is near the analyst consensus price target of $194, with support at $179 and resistance at $185.
The outlook for PM is cautiously optimistic, driven by its strong brand portfolio, including IQOS, and consistent cash flow generation. Investment opportunities lie in its dividend yield and potential for margin recovery. Key risks include regulatory challenges, illicit market growth in Europe, and ongoing cost inflation. Analyst consensus remains bullish, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
